NCT03365297View on ClinicalTrials.gov

Therapeutics in Active Prostate Cancer Surveillance

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Apalutamide

240mg (4x60mg) oral tablets daily over a max. of 90 days

Trial Locations (1)

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust/Addenbrookes Hospital, Cambridge

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

CCTU- Cancer Theme

OTHER

NCT03365297 - Therapeutics in Active Prostate Cancer Surveillance | Biotech Hunter | Biotech Hunter